

**Blue Cross Blue Shield/Blue Care Network of Michigan  
Medication Authorization Request Form**



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

| PATIENT INFORMATION   | PHYSICIAN INFORMATION                  |
|---|--|
| <b>Name</b>   | <b>Name</b>                            |
| <b>ID Number</b>  | <b>Specialty</b>                       |
| <b>D.O.B.</b> ___/___/___ MM/DD/YYYY<br><input type="checkbox"/> Male <input type="checkbox"/> Female | <b>Address</b>                         |
| <b>Diagnosis</b>  | <b>City /State/Zip</b>                 |
| <b>Drug Name</b> <b>BERINERT</b>  | <b>Phone:</b>                          |
| <b>Dose and Quantity</b>  | <b>Fax:</b>                            |
| <b>Directions</b>   | <b>NPI</b>                             |
| <b>Date of Service(s)</b>   | <b>Contact Person</b>                  |
|   | <b>Contact Person<br/>Phone / Ext.</b> |

**STEP 1: DISEASE STATE INFORMATION**

**Required Demographic Information:**

Patient Weight: \_\_\_\_\_ kg

Patient Height: \_\_\_\_\_ ft \_\_\_\_\_ inches

Will the provider be administering the medication to the FEP member within the health plan's geographic service area?

Yes  No *If No, a prior authorization is not required through this process.*

**Prior authorizations are required for FEP members that will be serviced by a provider within the health plan's geographic service area. If you are not a provider in the geographic service area, please contact the health plan for questions regarding the FEP member's benefit requirements.**

Is this member's FEP coverage primary or secondary coverage?

If primary, continue with question set.

If secondary, **an authorization is not needed through this process. Please contact the member's primary coverage for determination of benefit and additional information.**

**Site of Care:**

A. At what location will the member be receiving the requested medication?

Physician's office, home infusion, non-hospital affiliated ambulatory infusion center.

Outpatient hospital infusion center. Please provide the name of the infusion center and rationale why the patient must receive this medication in a hospital outpatient setting.

Other. Please specify. \_\_\_\_\_

**Criteria Questions:**

1. What is the patient’s diagnosis?
  - Hereditary Angioedema (HAE)
  - Other diagnosis (*please specify*): \_\_\_\_\_
2. Is Berinert being used to treat acute attacks or for the routine prevention of hereditary angioedema?  
**Please select answer below:**
  - Acute attacks **OR**  Routine prevention
3. Will the patient also be using another agent for treating **ACUTE** attacks of hereditary angioedema (e.g., Fira zyr/Sajazir, Kalbitor, Ruconest)?  Yes\*  No  
 \*If **YES**, specify the medication: \_\_\_\_\_
4. Has the patient been on Berinert continuously for the last **6 months, excluding samples**?  
**Please select answer below:**
  - NO** – this is **INITIATION** of therapy, please answer the following questions:
    - a. Does the patient have a normal C1 inhibitor as confirmed by laboratory testing? **Select answer below:**
      - Yes:** Please answer the following questions:
        - i. Does the patient have a F12, angiopoietin-1, plasminogen, or kininogen-1 (KNG1) gene mutation as confirmed by genetic testing?  Yes  No
        - ii. Does the patient have a documented family history of angioedema?  Yes\*  No  
 \*If **YES**, is the angioedema refractory to a trial of high-dose antihistamine such as cetirizine for at least one month?  
 Yes  No
      - No:** Please answer the following questions:
        - i. Does the patient have a C1 inhibitor deficiency or dysfunction as confirmed by laboratory testing?  Yes  No
        - ii. Is the patient’s C4 level below the lower limit of normal as defined by the laboratory performing the test?  Yes  No
        - iii. Does the patient have a normal C1-INH antigenic level as defined by the laboratory performing the test? **Answer below:**
          - Yes:** Does the patient have a C1-INH functional level less than 50% or a C1-INH functional level below the lower limit of normal as defined by the laboratory performing the test?  Yes  No
          - No:** Is the patient’s C1 inhibitor (C1-INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test?  Yes  No
  - YES** – this is a **PA renewal for CONTINUATION** of therapy, please answer the following question:
    - a. Has the patient experienced a reduction in severity and/or duration of hereditary angioedema attacks?  Yes  No

Chart notes are required for the processing of all requests. Please add any other supporting medical information necessary for our review (required)

Coverage will not be provided if the prescribing physician’s signature and date are not reflected on this document.

Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member’s ability to regain maximum function

| Physician’s Name  | Physician Signature  | Date   |
|---|--|--|
| <b>Step 2:</b><br>Checklist <ul style="list-style-type: none"> <li><input type="checkbox"/> Form Completely Filled Out</li> <li><input type="checkbox"/> Provide chart notes</li> </ul> |  | <input type="checkbox"/> Attach test results   |
| <b>Step 3:</b><br>Submit  | <b>By Fax: BCBSM Specialty Pharmacy Mailbox</b><br><b>1-877-325-5979</b> | <b>By Mail: BCBSM Specialty Pharmacy Program</b><br><b>P.O. Box 312320, Detroit, MI 48231-2320</b> |

**Confidentiality notice:** This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.